Resilience and Quality of Life Among Cancer Survivors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03466762|
Recruitment Status : Not yet recruiting
First Posted : March 15, 2018
Last Update Posted : March 16, 2018
The main aim of this study is to evaluate the impact of head & neck cancer and brain tumors on lives of patients in Pakistan. To the best of the investigators knowledge this will be the first in-depth study to evaluate resilience and quality of life (QoL) among this group of patients. These patients encounter challenges as they battle to maintain optimistic outlook towards life. Resilience and QoL among them changes over time and may be modifiable towards increased well-being. Resilience and QoL are critical components during diagnosis, treatment, survivorship, and at the end of life. Hence, these are important traits for promoting positive psychological well-being. Through this study the investigators will be able to identify problems faced by such patients in our setting. the investigators will be able to plan appropriate interventions to improve a person's resiliency and quality of life, reduce depression and anxiety, and increase their satisfaction with life. This study is also aimed to inform healthcare providers and researchers regarding protective or risk characteristics for coping with cancer. Practices and resilience interventions may improve well-being and adherence to care guidelines.
The objectives of our study are:
- To determine resilience and quality of life scores after treatment separately for head & neck cancer and Brain tumor patients in Pakistan.
- To evaluate important factors associated with resilience and quality of life after treatment separately for head & neck cancer and Brain tumor patients in Pakistan.
• To examine the relationship between resilience and quality of life after treatment separately for head & neck cancer and Brain tumor patients in Pakistan.
It will be an analytical cross sectional study design. The study will be conducted at the Aga Khan University Hospital, Karachi. Study participants will be men and women greater than 18 years, with brain tumors or head & neck cancer fulfilling the eligibility criteria. Approximately 250 patients will be recruiting with brain tumors and 250 with head & neck cancer. Validated tools will be used to measure resilience and QoL.
|Condition or disease||Intervention/treatment|
|Mental Health Wellness 1||Other: Non applicable|
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Resilience and Quality of Life of Head & Neck Cancer and Brain Tumor Survivors in Pakistan|
|Estimated Study Start Date :||April 1, 2018|
|Estimated Primary Completion Date :||November 30, 2018|
|Estimated Study Completion Date :||March 31, 2019|
- Other: Non applicable
- Resilience [ Time Frame: April 2018-March 2019 ]Resilience will be measured by Wagnild & Young's 14 Item A high score represents better resilience. The respondent's choice ranges from 1 (Strongly Disagree) to 7 (Strongly Agree). The scale uses total scores rather than scores of individual items.
- Quality of life [ Time Frame: April 2018-March 2019 ]Quality of life will be measured by European Organization of Research and Treatment Of Cancer tool general (EORTC QLQ-C30) AND European Organization of Research and Treatment Of head and Neck cancer (EORTC QLQ-H&N35) AND European Organization of Research and Treatment Of Brain tumor ( EORTC QLQ-BN20) All of the scales and single-item measures scores range from 0 to 100. A high scale score represents a higher response level.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03466762
|Contact: Nida Zahid||922134864287 ext firstname.lastname@example.org|
|Contact: Wardah Khalid||922124864287 ext email@example.com|
|Aga Khan University||Not yet recruiting|
|Karachi, Sindh, Pakistan, 74800|
|Contact: Nida Zahid, MSC 92214864287 ext 4287 firstname.lastname@example.org|
|Contact: wardah Khalid, MSc 92214864287 ext 4287 email@example.com|